{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000741","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.419908+00:00","generated_at":"2026-06-15T22:34:17.831306+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Mirum Q1 2023 LIVMARLI sales $29.1M, up 167% YoY; closed $316M convertible note","bullets":["Net product sales for LIVMARLI $29.1M in Q1 2023 vs $10.9M in Q1 2022, a 167% increase.","Total revenue $31.6M; operating expenses $58.7M; cash $232.1M as of March 31, 2023.","FDA approved label expansion for LIVMARLI to include infants 3 months+ in Alagille syndrome.","sNDA for LIVMARLI in PFIC accepted with PDUFA date December 13, 2023.","Closed $316.3M upsized convertible notes offering at 4.00% due 2029; repurchased 9.75% royalty obligation."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000741","json":"https://secwatch.observer/filing/0001157523-23-000741.json","markdown":"https://secwatch.observer/filing/0001157523-23-000741.md","text":"https://secwatch.observer/filing/0001157523-23-000741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000115752323000741/0001157523-23-000741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000115752323000741/a53394174.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:34:17.831306+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d676e0257dfd7efe30f39c52bf865d2d19b4d26a","claim":"Mirum Pharmaceuticals, Inc. reported first quarter 2023 results: revenue $31.6 million total revenue, including net product sales for LIVMARLI® (maralixibat) oral solution of $29.1 million.","evidence_excerpt":"Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update - $31.6 million total revenue, including net product sales for LIVMARLI ® (maralixibat) oral solution of $29.1 million, for first quarter 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000115752323000741/0001157523-23-000741-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Revenue","value":"$31.6 million total revenue, including net product sales for LIVMARLI® (maralixibat) oral solution of $29.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}